Peptide Nucleic Acid Antisense for Selective Nav1.7 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Nav1.7 selective inhibitors for treating chronic pain face challenges due to non-specific binding to voltage-gated sodium channels, leading to adverse effects and inadequate analgesic efficacy, with issues related to molecular size, selectivity, and distribution to CNS tissues.
Innovation Solution
A peptide nucleic acid derivative that specifically targets the 3' splice site of the SCN9A pre-mRNA to induce skipping of exon 4, reducing Nav1.7 expression by interfering with splicing, thereby providing a selective and effective approach to treat pain conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are used to target Nav1.7, then selective inhibition of Nav1.7 can be achieved, but non-specific binding to other VGSC subtypes occurs leading to adverse effects
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that bind to SCN9A pre-mRNA to prevent Nav1.7 protein synthesis. This indirect approach avoids direct binding to VGSC active sites, thereby eliminating non-specific inhibition of other sodium channel subtypes while maintaining selective reduction of Nav1.7 expression.
Solution Approach 2:
The patent replaces the mechanical/chemical binding mechanism of small molecule inhibitors (which physically block channel pores) with a genetic-level intervention using antisense oligonucleotides. This substitution occurs at the transcriptional level, preventing mRNA translation into Nav1.7 protein without affecting other VGSC subtypes.
2Reliability
If lidocaine is administered systemically to treat chronic pain, then Nav1.7 inhibition can be achieved, but non-specific inhibition of other VGSC subtypes causes side effects
Solution Approach 1:
The patent employs antisense oligonucleotides as intermediary agents that selectively target SCN9A pre-mRNA in the central nervous system. This approach provides localized gene silencing at the target site without requiring systemic circulation of broad-spectrum inhibitors, thereby achieving analgesic efficacy while minimizing off-target effects on other VGSC subtypes.
Solution Approach 2:
The patent achieves localized action of the antisense oligonucleotides within CNS tissues where Nav1.7 is expressed. The oligonucleotides concentrate at the site of action (spinal cord and brain) to inhibit Nav1.7 transcription locally, avoiding systemic inhibition of other sodium channels in peripheral tissues.
3Reliability
If Nav1.7 selective inhibitors are designed with appropriate molecular size, then selectivity improves, but distribution to CNS tissues becomes limited
Solution Approach 1:
The patent replaces small molecule inhibitors with antisense oligonucleotides, fundamentally changing the mechanism from direct channel blocking to gene transcription inhibition. This substitution enables CNS penetration through alternative pathways (such as intrathecal administration or blood-brain barrier transport mechanisms) that are not constrained by the molecular size limitations affecting small molecule distribution.
Solution Approach 2:
The patent changes the physical-chemical parameters of the therapeutic agent from small molecule characteristics (low molecular weight, lipophilicity) to oligonucleotide characteristics (higher molecular weight, polar backbone). This parameter change allows for different administration routes and distribution patterns, achieving CNS penetration through mechanisms such as convection-enhanced delivery or targeted transport rather than passive diffusion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide nucleic acid derivative effectively reduces Nav1.7 expression in neuronal cells, offering a safer and more potent analgesic solution with improved selectivity and tissue distribution, potentially overcoming the limitations of existing Nav1.7 inhibitors.
Implementation Method 1
the compound of Formula I possesses at least a 10-mer complementary overlap with a 14-mer pre-mRNA sequence of [(5'→3') UGUUUAGGUACACU (SEQ ID NO: 2)] within the human SCN9A pre-mRNA
Data Source
AI summary
The current invention provides peptide nucleic acid derivatives targeting the 3′ splice site of exon 4 in the human SCN9A pre-mRNA. The peptide nucleic acid derivatives potently induce SCN9A mRNA splice variant(s) lacking the SCN9A exon 4 in cells, and are useful to safely treat pains or conditions involving Nav1.7 activity.